Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04192266 · ClinicalTrials.gov registry record · Phase 3
Estrogen and Fear in PTSD
A Phase 3 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 3
- Development phase
- 83
- Enrollment target
NCT04192266 is a Phase 3 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 83 participants.
The verdict
NCT04192266, a Phase 3 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 83 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine if taking a pill of estradiol (E2) together with prolonged exposure (PE) therapy can improve this treatment outcome in women diagnosed with Post-Traumatic Stress Disorder (PTSD). 80 subjects will take part in this research study across UTHealth Houston and UPenn (40 subjects at each site). Participants will be randomized into one of two groups, PE + E2 or PE + placebo. The study will include preliminary screening and baseline visits, experimental visits, and therapy visits over the course of six weeks. Several follow-up visits will take place.
Interventions
- DRUG Placebo oral tablet
- DRUG Estradiol
- BEHAVIORAL Prolonged Exposure (PE) therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2020-06-24 |
| Est. Completion | 2024-12-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04192266
The ClinicalTrials.gov registry entry for NCT04192266 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo oral tablet is the first listed.
NCT04192266 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04192266 about?
NCT04192266 is a clinical study titled "Estrogen and Fear in PTSD". The purpose of this research study is to determine if taking a pill of estradiol (E2) together with prolonged exposure (PE) therapy can improve this treatment outcome in women diagnosed with Post-Traumatic Stress Disorder (PTSD). 80 subjects will take part in this research study across UTHealth Hous...
What is the current status of trial NCT04192266?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 83 participants. The study started on 2020-06-24. Estimated completion is 2024-12-02.
What interventions are being tested in trial NCT04192266?
The interventions under investigation include: Placebo oral tablet (DRUG), Estradiol (DRUG), Prolonged Exposure (PE) therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT04192266?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.